Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis

Jeremy Hull, Anne H Thomson

Abstract

Background—Disease severity in patients with cystic fibrosis shows marked variability. Attempts to explain this phenotypic heterogeneity on the basis of CFTR genotype have had limited success. A study was undertaken to test the hypothesis that naturally occurring variants of the pro-inflammatory cytokine tumour necrosis factor alpha (TNF-α) and the detoxifying enzyme glutathione S-transferase M1 (GSTM1) could influence disease severity in cystic fibrosis.

Methods—Fifty three children with cystic fibrosis were studied. To allow for the effect of age, all clinical details were collected during the eighth year of age. The subjects were divided into groups, both according to the presence or absence of the TNF2 TNF-α -308 promoter polymorphism (n = 20), and by homozygosity for the null allele of GSTM1 (n = 26).

Results—Percentage predicted forced expiratory volume in one second (FEV1) and weight z scores were significantly lower in the TNF2 group (mean difference (95% confidence intervals) for FEV1, 11.6% (1.7 to 21.5) and 0.59 (0.06 to 1.12) for weight z score). The Chrispin-Norman chest radiographic score was significantly higher and the Shwachman score was significantly lower in patients homozygous for the GSTM1 null allele.

Conclusions—Two independent genetic factors have been identified which appear to influence disease severity in cystic fibrosis. These results support the contention that inflammation in cystic fibrosis contributes to tissue damage. Isolation of further such factors may lead to identification of patients at risk of more severe disease and allow targeted aggressive therapy in this group.

(Thorax 1998;53:1018–1021)

Keywords: cystic fibrosis; disease severity; genetic modifiers

Cystic fibrosis is the most severe autosomal recessive disease in Caucasian populations and affects nearly 7000 people in the UK. The disease is characterised by pancreatic dysfunction and progressive endobronchial inflammation and infection. The median life expectancy is now approximately 30 years. There is, however, considerable heterogeneity in disease severity between different individuals with cystic fibrosis. Attempts to link phenotype with specific CFTR mutations have had some success, particularly for pancreatic disease status. Nevertheless, marked disease variability amongst individuals with the same CFTR genotype, who share a similar environment and who attend the same cystic fibrosis centre, suggests the presence of other genetic elements at non-cystic fibrosis loci that can affect disease severity. Attempts have been made to identify disease modifying genes in the cystic fibrosis mouse. This approach is hampered by the shortcomings of the cystic fibrosis mouse as a model for the human disease, particularly the observation that gastrointestinal problems are the greatest cause of mortality in these animals. Most of the morbidity and mortality in human subjects with cystic fibrosis is as a result of lung disease. The mechanism of lung damage in cystic fibrosis is not fully understood. Pulmonary inflammation is intense, persistent, and of early onset. It seems likely that this overexuberant host inflammatory response, possibly via increased pulmonary oxidative stress or increased free elastase activity, is responsible for most of the lung damage that occurs.

Tumour necrosis factor alpha (TNF-α) is a pro-inflammatory cytokine produced predominantly by macrophages. It is found in high concentrations in the lungs of patients with cystic fibrosis and is likely to be important in promoting the intense neutrophil dominated inflammation found in this disease. One study has found an inverse relationship between concentrations of TNF-α in the sputum of patients with cystic fibrosis and lung function. These observations suggest that the severity of lung disease in cystic fibrosis may be related to the genetic propensity of the host to produce TNF-α. A polymorphism in the promoter region of the TNF-α gene, at nucleotide -308 relative to the transcription start site, may be important in determining the host TNF-α response. There are two alleles at the polymorphic site, TNF1 and TNF2. The TNF2 allele is associated with higher constitutive and inducible levels of transcription of TNF-α than the TNF1 allele. The TNF2 allele has shown a positive association with a number of disease states and has recently been found to be associated with an increased risk of developing chronic bronchitis.

The major local pulmonary antioxidant is glutathione which is present in high concentrations in the epithelial lining fluid. Glutathione S-transferases (GST) detoxify harmful organic hydroperoxides which form as a result of exposure to oxidant stress, such as that found in the lungs of patients with cystic fibrosis, by conjugating them with glutathione, thereby preventing further pulmonary damage. One of this...
family of enzymes, GSTM1, is represented by two functionally active alleles (GSTM1-A and GSTM1-B) and by one null allele (GSTM1-0). The latter does not produce a protein product because of an expanded deletion. In most populations studied, 40–60% of subjects are GSTM1-0 homozygotes. These subjects have been shown to have increased risk of various cancers, pulmonary emphysema, and chronic bronchitis. The homozygous null genotype has also been shown in one study to be associated with an earlier diagnosis of cystic fibrosis and death before the age of five years, suggesting that GSTM1-0 homozygosity in cystic fibrosis predisposes to more severe lung disease.

In this study we have examined the effects of the -308 TNF-α polymorphism and the GSTM1 genotype on disease severity in 53 children with cystic fibrosis.

Methods

Subjects

The study group consisted of 53 children (20 girls) with cystic fibrosis. All subjects attended the Oxford Cystic Fibrosis Clinical Centre. The diagnosis of cystic fibrosis was made on the basis of two positive sweat tests. In order to compare disease severity between different subjects without the influence of age, an obvious confounding factor, all clinical data on the children were collected during their eighth year of life. By this age most children are able to perform reliable forced expiratory manoeuvres for the purposes of lung function testing. Children were eligible for the study if clinical data, including lung function data, were available for their eighth year, and if DNA taken for CFTR genotyping had been stored.

Clinical Data

Children at the Oxford Cystic Fibrosis Centre undergo a comprehensive review each year. As part of this review their weight is recorded and chest radiographs are scored using the Chrispin-Norman system. This scoring system gives a numerical score for the chest radiograph with a maximum of 38 indicating most severe disease. A Shwachman score of disease severity is also calculated. The Shwachman score is based on assessments of general activity, nutritional status, physical examination and chest radiography, with a maximum of 100 indicating the mildest disease. Lung function (including forced expiratory volume in one second, FEV₁) is measured using a Vitalograph spirometer (Vitalograph Ltd, Buckingham, UK). Sputum or cough swabs are also collected for microbiological testing. Children were recorded as being positive for Pseudomonas aeruginosa if this organism had been isolated on at least one occasion. These five clinical parameters were used as markers of disease severity.

Genotype Analysis

DNA samples stored at the time of CFTR genotyping were used for analysis. The presence of the -308 TNF-α polymorphism was detected using the method of Wilson and colleagues with the adaptation of Huang and co-workers. Briefly, a 345 base pair (bp) fragment of DNA was amplified using the polymerase chain reaction (PCR) from each sample of genomic DNA. The 3’ primer used in the PCR reaction incorporates the -308 polymorphic site into an NcoI restriction site. If the TNF1 allele is present, the subsequent DNA fragment will be cut by NcoI giving fragments of 325 and 20 bp. If the TNF2 allele is present (G to A transition) the NcoI site is destroyed and no cutting occurs. The fragments were resolved using a 2% NuSieve GTG agarose gel (FMC BioProducts, Rockland, Maine, USA) and visualised by ethidium bromide staining.

GSTM1-0 homozygotes were also detected by PCR. GSTM1 specific primers were used to amplify a 271 bp fragment from exon 3 of the CFTR gene, using primers 3i3 (ATTCACCAGATTTCG-CTTGGA), was used as an internal standard for each PCR reaction. The fragments were resolved and visualised as described for the TNF-α analysis.

Statistical Analysis

Data for FEV₁, chest radiographic score, weight z score, and Shwachman score were normally distributed and comparisons between groups were made using the two tailed Student’s t test. Analysis of the presence or absence of Pseudomonas aeruginosa by the age of eight years was carried out using the χ² test.

Results

Fifty three children were studied. The clinical details of the study population are shown in table 1. All children were assessed at the age of eight years in the Oxford Cystic Fibrosis Centre between 1984 and 1997. There was no difference in the distribution of date of review between any of the study groups; any effect of changes of treatment in more recent years thus affected all groups equally. Analyses of the TNF-α promoter polymorphism and the GSTM1 allele were successful in all subjects. The allele frequency for the TNF1 allele was 0.81 and for the TNF2 allele was 0.19; 49% of the study population were GSTM1 deficient (GSTM1-0/0).

Table 2 shows the recorded clinical parameters for the study group split according to the TNF-α -308 polymorphism genotype. Only one subject was homozygous for the
Hull, Thomson

The type of CFTR mutations present. This clinical heterogeneity can be explained by which could explain why some patients seem to likely to be genetic variability in their patients cystic fibrosis have long been aware that there is doctors who care for children and adults with cystic fibrosis have long been aware that there is variability in disease severity, even amongst those patients who are homozygous for the F508 mutation. This was seen (data not shown). All the subjects were classified according to whether they were carried any of these defined mutations. A small number of missense mutations have been shown to be associated with residual CFTR function and a mild clinical phenotype. The proportion of subjects homozygous for the AF508 mutation was the same in all study groups. A small number of missense mutations have been shown to be associated with residual CFTR function and a mild clinical phenotype. None of the patients in the study group carried any of these defined mutations. When the subjects were classified according to whether they were AF508 homozygous or AF508 compound heterozygous no effect on disease severity was seen (data not shown). All but one of the study subjects were pancreatic insufficient.

### Discussion

Doctors who care for children and adults with cystic fibrosis have long been aware that there is likely to be genetic variability in their patients which could explain why some patients seem to do considerably better than others. Some of this clinical heterogeneity can be explained by the type of CFTR mutations present. However, given that there is clearly variability in disease severity, even amongst those patients who are homozygous for the AF508 mutation, it seems likely that other factors are also important.

A previous study which has addressed this problem examined the effects of variation in alpha,-antitrypsin (α-AT) allotypes on cystic fibrosis phenotype. This study showed a significant association between the S and Z α-AT mutants and earlier onset of pulmonary colonisation with P aeruginosa in patients with cystic fibrosis. The effect was small and there was no apparent effect on lung function. Nevertheless, this study suggested that non-CFTR genetic factors which influence cystic fibrosis phenotype could be identified.

In this study we have examined the effect of genetic variability in two genes, TNF-α and GSTM1, which were predicted to be involved in the pathogenesis of cystic fibrosis. We have shown that the TNF2 allele and the null GSTM1 homozygous state are positively associated with markers of disease severity. The study was low powered to detect small effects and it is possible that some measures of disease severity which only tended to be worse in these groups of patients would be shown to be significantly different by larger studies.

The TNF2 allele was present in this study at a frequency of 0.19. This is similar to that found in other studies in Caucasian populations. It is possible that the observed effects of the presence of the TNF2 allele result not from alteration of TNF-α production but rather because of linkage of TNF2 to nearby functionally unrelated genes. The TNF-α gene is located within the class III region of the major histocompatibility complex.

The increased frequency of the TNF2 allele in patients with systemic lupus erythematosus has been shown to be dependent on the linkage disequilibrium between TNF-α and HLA-DR3. McGuire and colleagues were, however, able to show that the effects of the TNF2 allele in cerebral malaria were independent of linkage to HLA genes. In this study we have not addressed the question of linkage disequilibrium with other genes. However, the central role of TNF-α in regulating inflammatory responses, and the correlation between TNF-α levels and cystic fibrosis disease severity, suggests that the association between the TNF2 allele and

### Table 2: Clinical markers of disease severity split by TNF-α genotype

<table>
<thead>
<tr>
<th></th>
<th>TNF1/TNF2 (n=20)</th>
<th>Mean difference</th>
<th>95% CI</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean FEV1 (% predicted)</td>
<td>87.8 76.2</td>
<td>11.6 1.7 to 21.5</td>
<td>0.02</td>
<td></td>
</tr>
<tr>
<td>Mean weight z score</td>
<td>−0.37 −0.96</td>
<td>0.59 0.06 to 1.12</td>
<td>0.03</td>
<td></td>
</tr>
<tr>
<td>Mean Chrispin-Norman chest radiographic score</td>
<td>12.1 14.5</td>
<td>2.4 −5.9 to 1.1</td>
<td>0.17</td>
<td></td>
</tr>
<tr>
<td>Mean Shwachman score</td>
<td>82.0 78.2</td>
<td>3.8 −1.7 to 9.4</td>
<td>0.17</td>
<td></td>
</tr>
<tr>
<td>No. positive for P aeruginosa</td>
<td>10 7</td>
<td>Null (n=26)</td>
<td>0.02</td>
<td></td>
</tr>
<tr>
<td>No. AF508 homozygous</td>
<td>22 14</td>
<td>Null (n=26)</td>
<td>0.03</td>
<td></td>
</tr>
</tbody>
</table>

### Table 3: Clinical markers of disease severity split by GSTM1 genotype

<table>
<thead>
<tr>
<th></th>
<th>Normal (n=27)</th>
<th>Null (n=26)</th>
<th>Mean difference</th>
<th>95% CI</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean FEV1 (% predicted)</td>
<td>86.8 79.8</td>
<td>7.0 −2.9 to 16.9</td>
<td>0.16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean weight z score</td>
<td>−0.56 −0.63</td>
<td>0.07 −0.47 to 0.61</td>
<td>0.79</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean Chrispin-Norman chest radiographic score</td>
<td>11.0 15.0</td>
<td>4 −7.3 to −0.8</td>
<td>0.02</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean Shwachman score</td>
<td>83.3 77.7</td>
<td>5.6 0.4 to 10.9</td>
<td>0.04</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. positive for P aeruginosa</td>
<td>6 11</td>
<td>Null (n=26)</td>
<td>0.12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. AF508 homozygous</td>
<td>17 19</td>
<td>Null (n=26)</td>
<td>0.43</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FEV1 = forced expiratory volume in one second.

TNF2 allele and for the purposes of analysis this subject has been included in the TNF1/TNF2 heterozygous group. For each of the clinical markers of disease severity the presence of the TNF2 allele tended to be associated with more severe disease. The percentage predicted FEV1 in the TNF1/TNF2 group (76%) was significantly lower than that for the TNF1 group (88%, p = 0.02). Weight z score was also significantly lower in the TNF1/TNF2 group (−0.96) than in the TNF1 group (−0.37, p = 0.03).

Table 3 shows the recorded clinical parameters for the study group split according to GSTM1 status. For each of the clinical markers of disease severity the patients homozygous for the null allele tended to have more severe disease. Both the chest radiographic score and the Shwachman score were significantly worse in the GSTM1-0/0 group.

The proportion of subjects homozygous for the AF508 mutation was the same in all study groups. A small number of missense mutations have been shown to be associated with residual CFTR function and a mild clinical phenotype. None of the patients in the study group carried any of these defined mutations. When the subjects were classified according to whether they were AF508 homozygous or AF508 compound heterozygous no effect on disease severity was seen (data not shown). All but one of the study subjects were pancreatic insufficient.
more severe disease found in this study is due to effects on TNF-α production. 

The effects of the GSTM1 null allele are easier to interpret. This allele produces no protein, and the correlation between the null allele detected by the PCR method and disease severity in the cystic fibrosis lung is reduced by 27% compared with the GSTM1 0/0 phenotype in patients with adenocarcinoma. This allele produces no protein, and the correlation between the null allele detected by the PCR method and disease severity in the cystic fibrosis lung is reduced by 27% compared with the GSTM1 0/0 phenotype in patients with adenocarcinoma.

In conclusion, we have shown that two independent genetic variants can influence disease severity in patients with cystic fibrosis. As would be expected, the effects of these factors within individual patients are small. Nevertheless, group comparisons—for example, for FEV1, which showed changes of more than 10%—suggest that these effects may be clinically important. This study supports the contention that the pulmonary inflammatory response is excessive and damages the host. It is possible that identification of further genetic modifiers will only increase our understanding of the pathogenesis of cystic fibrosis, but also allow identification of those patients who would most benefit from early intensive treatment.

If was supported by an Advanced Training Fellowship from the Wellcome Trust, UK. The Oxford Cystic Fibrosis Centre is supported by the Cystic Fibrosis Trust. The authors thank Dr. Ann Harris for her help and support.


---

**References:**

Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis

Jeremy Hull and Anne H Thomson

*Thorax* 1998 53: 1018-1021
doi: 10.1136/thx.53.12.1018

Updated information and services can be found at:
http://thorax.bmj.com/content/53/12/1018

These include:

**References**

This article cites 33 articles, 10 of which you can access for free at:
http://thorax.bmj.com/content/53/12/1018#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Cystic fibrosis (525)
- Molecular genetics (211)
- Airway biology (1100)
- Genetic screening / counselling (88)
- Inflammation (1020)
- Lung function (773)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/